Make Better Decisions - Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

Get the Book: Make Better Decisions

Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

PDF eBook: Just $10 Get Print Book on Amazon

Serving leading biopharmaceutical companies globally:

Merck
McKesson
Boehringer Ingelheim
Express Scripts
Mallinckrodt
Baxter

Last Updated: November 22, 2019

DrugPatentWatch Database Preview

Details for Patent: 7,767,223

See Plans and Pricing

« Back to Dashboard

Which drugs does patent 7,767,223 protect, and when does it expire?

Patent 7,767,223 protects OZURDEX and is included in one NDA.

This patent has sixteen patent family members in ten countries.

Summary for Patent: 7,767,223
Title:Methods for reducing or preventing transplant rejection in the eye and intraocular implants for use
Abstract:Methods for reducing or preventing transplant rejection in the eye of an individual are described, comprising: a) performing an ocular transplant procedure; and b) implanting in the eye a bioerodible drug delivery system comprising an immunosuppressive agent and a bioerodible polymer.
Inventor(s): Wong; Vernon G. (Menlo Park, CA)
Assignee: Allergan, Inc. (Irvine, CA)
Application Number:11/180,079
Patent Claim Types:
see list of patent claims
Use; Compound; Delivery; Device;

Drugs Protected by US Patent 7,767,223

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Submissiondate
Allergan OZURDEX dexamethasone IMPLANT;INTRAVITREAL 022315-001 Jun 17, 2009 RX Yes Yes   Start Trial   Start Trial Y   Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Patented / Exclusive Use >Submissiondate

International Family Members for US Patent 7,767,223

Country Patent Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Austria 306951   Start Trial
Australia 2002236495   Start Trial
Australia 2006201271   Start Trial
Australia 3649502   Start Trial
Brazil 0115772   Start Trial
Canada 2429998   Start Trial
Germany 60114229   Start Trial
>Country >Patent Number >Estimated Expiration >Supplementary Protection Certificate >SPC Country >SPC Expiration

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Medtronic
Moodys
McKesson
Dow
McKinsey
Express Scripts

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.